Literature DB >> 8620790

Effect of nifedipine on rectoanal motility.

E Chrysos1, E Xynos, G Tzovaras, O J Zoras, J Tsiaoussis, S J Vassilakis.   

Abstract

PURPOSE: Based on the rationale that the calcium channel blocker, nifedipine, decreases lower esophageal sphincter pressure in achalasia, a prospective controlled trial was performed to evaluate the effect of sublingual nifedipine on the anal sphincter of controls and patients with high anal resting pressures.
METHODS: Ten age-matched and sex-matched controls without evidence of anal disorder and ten patients with hemorrhoids and/or fissure-in-ano were included in the study. Anorectal manometry, with an eight-channel, water-perfused catheter was performed on all patients before and 30 minutes after administration of 20 mg of sublingual nifedipine.
RESULTS: Nifedipine significantly reduced anal resting pressure in both controls and patients by approximately 30 percent (P < 0.001 and P < 0.0001, respectively). A significant reduction was also noted in the length of high-pressure zone of the anal sphincter (P < 0.02 for both groups) and in the frequency (controls, P < 0.05; patients, P < 0.03) and amplitude (controls, P < 0.03; patients, P < 0.009) of slow waves in both groups, whereas the presence, frequency, and amplitude of ultraslow waves were significantly reduced only in the patient group (P < 0.05; P < 0.01; P < 0.0005, respectively).
CONCLUSION: Nifedipine reduces the activity of the internal anal sphincter both in controls and patients with high anal resting pressure. The drug might be of some use in relieving symptoms in patients with hemorrhoids or anal fissure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620790     DOI: 10.1007/bf02068078

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  14 in total

Review 1.  Neuromyogenic properties of the internal anal sphincter: therapeutic rationale for anal fissures.

Authors:  R Bhardwaj; C J Vaizey; P B Boulos; C H Hoyle
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Anal fissure: the changing management of a surgical condition.

Authors:  A G Acheson; J H Scholefield
Journal:  Langenbecks Arch Surg       Date:  2003-11-18       Impact factor: 3.445

3.  Anal fissure.

Authors:  Karen N Zaghiyan; Phillip Fleshner
Journal:  Clin Colon Rectal Surg       Date:  2011-03

Review 4.  Current concepts in anal fissures.

Authors:  Abraham A Ayantunde; Samuel A Debrah
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

Review 5.  A review of chronic anal fissure management.

Authors:  E E Collins; J N Lund
Journal:  Tech Coloproctol       Date:  2007-08-03       Impact factor: 3.781

6.  Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, randomized, double-blind study.

Authors:  Pasquale Perrotti; Patrizia Dominici; Enzo Grossi; Renata Cerutti; Carmine Antropoli
Journal:  Can J Surg       Date:  2010-02       Impact factor: 2.089

7.  Combined approach in the treatment of chronic anal fissures.

Authors:  S Vershenya; J Klotz; A Joos; D Bussen; A Herold
Journal:  Updates Surg       Date:  2015-04-21

Review 8.  Anal Fissure.

Authors:  Jennifer Sam Beaty; M Shashidharan
Journal:  Clin Colon Rectal Surg       Date:  2016-03

9.  Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity.

Authors:  Panagiotis Katsinelos; Jannis Kountouras; George Paroutoglou; Athanasios Beltsis; Grigoris Chatzimavroudis; Christos Zavos; Taxiarchis Katsinelos; Basilis Papaziogas
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

10.  Serum levels and possible haemodynamic effects following anorectal application of an ointment containing nifedipine and lignocaine : a study in healthy volunteers.

Authors:  Pasquale Perrotti; Lucia Grumetto; Francesco Barbato; Carmine Antropoli
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.